RNA	O
damage	O
and	O
inhibition	O
of	O
neoplastic	B-Cell
endothelial	I-Cell
cell	I-Cell
growth	O
:	O
effects	O
of	O
human	O
and	O
amphibian	O
ribonucleases	O
.	O

Angiogenesis	O
defines	O
the	O
many	O
steps	O
involved	O
in	O
the	O
growth	O
and	O
migration	O
of	O
endothelial	B-Cell
cell	I-Cell
-	O
derived	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
.	O

This	O
process	O
is	O
necessary	O
for	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	B-Cancer
,	O
and	O
considerable	O
effort	O
is	O
being	O
expended	O
to	O
find	O
inhibitors	O
of	O
tumor	B-Cancer
angiogenesis	O
.	O

This	O
usually	O
involves	O
screening	O
of	O
potential	O
anti	O
-	O
angiogenic	O
compounds	O
on	O
endothelial	B-Cell
cells	I-Cell
.	O

To	O
this	O
end	O
,	O
two	O
candidate	O
anti	O
-	O
angiogenic	O
RNA	O
-	O
damaging	O
agents	O
,	O
onconase	O
and	O
(	O
-	O
4	O
)	O
rhEDN	O
,	O
were	O
screened	O
for	O
their	O
effects	O
on	O
endothelial	B-Cell
cell	I-Cell
proliferation	O
using	O
three	O
distinct	O
types	O
of	O
endothelial	B-Cell
cells	I-Cell
in	O
culture	O
:	O
HPV	O
-	O
16	O
E6	O
/	O
E7	O
-	O
immortalized	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	I-Cell
(	O
HUVECs	B-Cell
)	O
,	O
a	O
Kras	O
-	O
transformed	O
HPV	O
-	O
16	O
E6	O
/	O
E7	O
HUVEC	B-Cell
(	O
Rhim	O
et	O
al	O
.	O
,	O
Carcinogenesis	O
4	O
,	O
673	O
-	O
681	O
,	O
1998	O
)	O
,	O
and	O
primary	O
HUVECs	B-Cell
.	O

Onconase	O
similarly	O
inhibited	O
proliferation	O
in	O
all	O
three	O
cell	B-Cell
lines	I-Cell
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
3	O
-	O
1	O
.	O
0	O
microM	O
)	O
while	O
(	O
-	O
4	O
)	O
rhEDN	O
was	O
more	O
effective	O
on	O
immortalized	O
HUVEC	B-Cell
cell	I-Cell
lines	I-Cell
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
02	O
-	O
0	O
.	O
06	O
microM	O
)	O
than	O
on	O
primary	O
HUVECs	B-Cell
(	O
IC	O
(	O
50	O
)	O
>	O
0	O
.	O
1	O
microM	O
)	O
.	O

Differential	O
sensitivity	O
to	O
these	O
agents	O
implies	O
that	O
more	O
than	O
one	O
endothelial	B-Cell
cell	I-Cell
type	I-Cell
must	O
be	O
used	O
in	O
proliferation	O
assays	O
to	O
screen	O
for	O
novel	O
anti	O
-	O
angiogenic	O
compounds	O
.	O

